# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in p...
Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:PRGO) with a Buy and maintains $42 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Piper Sandler analyst Korinne Wolfmeyer maintains Perrigo (NYSE:PRGO) with a Overweight and raises the price target from $35...
CVS Health expands coverage to include the first OTC birth control pill in the U.S., offering accessible contraception without ...
-Bloomberg
https://www.washingtonpost.com/politics/2024/03/26/abortion-pill-supreme-court-arguments-mifepristone/The Supreme Court on Tues...
Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-sto...
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.